[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

81

1 the standpoint of having some broad overview, that we
2 could go into an hour of answering of that long menu
3 of questions.
4 They should be answered, and I think we
5 could do that if you would send them in writing. We
6 could answer them at a subsequent time in writing or
7 at the subsequent meetings.
8 But if you want to have some comments
9 about one of the points that he made, Larry?
10 DR. COREY: Well, let us just say that the
11 SCID -- I'm not sure you were listening to what I
12 said. The SCID mouse data were presented. Number
13 one, let me say that Carol Smith from your own company
14 is a co-author on the data in the SCID mouse paper,
15 which is in press at PNAS, and the Mosier paper, which
16 is also in press there.
17 We presented it as a positive finding of
18 the immunogen in someone who is vaccinia-primed being
19 maybe more analogous to the situation in the
20 seronegative patient as in the seropositive patient,
21 who is obviously primed and may be primed with a
22 variety of different strains, hence the nature of the
NEAL R. GROSS
COURT REPORTERS AND TRANSCRISERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]